Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus | NEJM - nejm.org

Original Article from The New England Journal of Medicine — Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus

Background Blood dendritic cell antigen 2 (BDCA2) is a receptor that is exclusively expressed on plasmacytoid dendritic cells, which are implicated in the pathogenesis of lupus erythematosus. Whethe… [+2587 chars]

full article...